Orexo AB (publ) (STO:ORX)
20.50
-0.10 (-0.49%)
Aug 1, 2025, 5:29 PM CET
Orexo AB Employees
Orexo AB had 110 employees as of December 31, 2024. The number of employees decreased by 6 or -5.17% compared to the previous year.
Employees
110
Change (1Y)
-6
Growth (1Y)
-5.17%
Revenue / Employee
5.10M SEK
Profits / Employee
-1.94M SEK
Market Cap
707.36M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 110 | -6 | -5.17% |
Dec 31, 2023 | 116 | -10 | -7.94% |
Dec 31, 2022 | 126 | 7 | 5.88% |
Dec 31, 2021 | 119 | -18 | -13.14% |
Dec 31, 2020 | 137 | 10 | 7.87% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Swedish Orphan Biovitrum AB | 1,806 |
Sectra AB | 1,296 |
Getinge AB | 11,791 |
Camurus AB | 256 |
Medicover AB | 47,256 |
Asker Healthcare Group AB | 4,030 |
Bonesupport Holding AB | 139 |
AddLife AB | 2,181 |
Orexo AB News
- 2 months ago - Orexo to present clinical data for OX640 at the EAACI Congress - PRNewsWire
- 4 months ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire
- 7 months ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 8 months ago - Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology - Seeking Alpha
- 8 months ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire
- 10 months ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire
- 10 months ago - Orexo AB reports Q3 results - Seeking Alpha
- 10 months ago - Orexo´s Nomination Committee for the Annual General Meeting 2025 - PRNewsWire